

## AMENDMENTS TO THE CLAIMS

This listing of claims replaces all previous versions, and listings, of claims pending in this application.

### Listing of Claims


1-161. (Canceled)

162. (Currently amended) A compound comprising a peptide chain having a sequence of amino acids  $CX^{IV}_1X^{IV}_2X^{IV}_3X^{IV}_4X^{IV}_5X^{IV}_6X^{IV}_7X^{IV}_8X^{IV}_9X^{IV}_{10}C$  ~~approximately 17 to 40 amino acids in length~~ that binds to a G-CSFR, wherein said ~~and contains a~~ sequence of amino acids is selected from the group consisting of GGGLLDICELKLQECARRCN (SEQ ID NO: 209); GRTGGLLDICELKLQECARRCN (SEQ ID NO: 210); LGIEGRTGGGLLDICELKLQECARRCN (SEQ ID NO: 211); LLDICEELKLQEAARRCN (SEQ ID NO: 212); LLDIAELKLQECARRCN (SEQ ID NO: 464); ~~KLLDICELKLQEAARRCN (SEQ ID NO: 213);~~ and LLDICELKLQECARRAN (SEQ ID NO: 343), and wherein each amino acid is indicated by standard one-letter abbreviation.

163. (Previously presented) The compound of claim 162, wherein said sequence of amino acids is GGGLLDICELKLQECARRCN (SEQ ID NO: 209).

164. (Previously presented) The compound of claim 162, wherein said sequence of amino acids is GRTGGLLDICELKLQECARRCN (SEQ ID NO: 210).

165. (Canceled) ~~The compound of claim 162, comprising a dimer having the structure of formula (VIII)~~



~~wherein  $R^1$  and  $R^2$  are independently selected from the sequences of amino acids of claim 1; formula (V);  $\beta A$  is a  $\beta$ -alanine residue;  $n1, n2, n3, n4, x$  and  $y$  are independently zero or one with the proviso that the sum of  $x$  and  $y$  is either one or two; and Lk is a terminal linking moiety selected from the group consisting of a disulfide bond, a carbonyl moiety, a C1-12 linking moiety optionally terminated with one or two NH linkages and optionally substituted at one or more available carbon atoms with a lower alkyl substituent, a lysine residue or a lysine amide.~~

166. (Previously presented) The compound of claim 162, containing a disulfide bond.
167. (Currently amended) The compound of ~~claim~~ ~~claims~~-162 wherein the N terminus of the peptide is coupled to a polyethylene glycol molecule.
168. (Previously presented) The compound of claim 162 wherein the N terminus of the peptide is acetylated.
169. (Previously presented) The compound of claim 162, wherein the C terminus of the peptide is amidated.
170. (Currently amended) A pharmaceutical composition comprising a therapeutically effective amount of the compound of ~~any claim~~-162, in combination with a pharmaceutically acceptable carrier.
171. (Withdrawn) A method for treating a patient who would benefit from administration of a GCSF modulator, comprising administering to the patient a therapeutically effective amount of the compound of claim 162.
172. (Withdrawn) The method of claim 171, wherein the G-CSF modulator is an agonist for the GCSFR.
173. (Withdrawn) The method of claim 171, wherein the patient suffers from a depressed neutrophil count.
174. (Withdrawn) The method of claim 173, wherein the depressed neutrophil count is associated with a condition selected from the group consisting of chemotherapy-induced neutropenia, AIDS induced neutropenia and community-acquired pneumonia-induced neutropenia.
175. (Previously presented) The compound of claim 162, wherein said sequence of amino acids is LGIEGRTGGGLLDICELKLQECARRCN (SEQ ID NO: 211).
176. (Previously presented) The compound of claim 162, wherein said sequence of amino acids is LLDICEELKLQEAARRCN (SEQ ID NO: 212).
177. (Currently amended)Previously presented) The compound of claim 162, wherein said sequence of amino acids is LLDIAELKLQECARRCN (SEQ ID NO: 464). ~~KLLDICELKLQEAARRCN (SEQ ID NO: 213)~~.

178. (Previously presented) The compound of claim 162, wherein said sequence of amino acids is LLDICELKLQECARRAN (SEQ ID NO:343).